Neural correlates of improved executive function following erythropoietin treatment in mood disorders

Background Cognitive dysfunction in depression and bipolar disorder (BD) is insufficiently targeted by available treatments. Erythropoietin (EPO) increases neuroplasticity and may improve cognition in mood disorders, but the neuronal mechanisms of these effects are unknown. This functional magnetic resonance imaging (fMRI) study investigated the effects of EPO on neural circuitry activity during working memory (WM) performance. Method Patients with treatment-resistant major depression, who were moderately depressed, or with BD in partial remission, were randomized to eight weekly infusions of EPO (40 000 IU) (N = 30) or saline (N = 26) in a double-blind, parallel-group design. Patients underwent fMRI, mood ratings and blood tests at baseline and week 14. During fMRI patients performed an n-back WM task. Results EPO improved WM accuracy compared with saline (p = 0.045). Whole-brain analyses revealed that EPO increased WM load-related activity in the right superior frontal gyrus (SFG) compared with saline (p = 0.01). There was also enhanced WM load-related deactivation of the left hippocampus in EPO-treated compared to saline-treated patients (p = 0.03). Across the entire sample, baseline to follow-up changes in WM performance correlated positively with changes in WM-related SFG activity and negatively with hippocampal response (r = 0.28–0.30, p < 0.05). The effects of EPO were not associated with changes in mood or red blood cells (p ⩾0.08). Conclusions The present findings associate changes in WM-load related activity in the right SFG and left hippocampus with improved executive function in EPO-treated patients. Clinical trial registration: clinicaltrials.gov: NCT00916552.

[1]  H. Siebner,et al.  Effects of Erythropoietin on Hippocampal Volume and Memory in Mood Disorders , 2015, Biological Psychiatry.

[2]  Maj Vinberg,et al.  Effects of Short-Term Cognitive Remediation on Cognitive Dysfunction in Partially or Fully Remitted Individuals with Bipolar Disorder: Results of a Randomised Controlled Trial , 2015, PloS one.

[3]  A. MacDonald,et al.  Brain Correlates of Cognitive Remediation in Schizophrenia: Activation Likelihood Analysis Shows Preliminary Evidence of Neural Target Engagement. , 2015, Schizophrenia bulletin.

[4]  R. Salvador,et al.  Brain functional changes across the different phases of bipolar disorder. , 2015, The British journal of psychiatry : the journal of mental science.

[5]  C. Harmer,et al.  Different neural and cognitive response to emotional faces in healthy monozygotic twins at risk of depression , 2014, Psychological Medicine.

[6]  Sophia Vinogradov,et al.  Intensive cognitive training in schizophrenia enhances working memory and associated prefrontal cortical efficiency in a manner that drives long-term functional gains , 2014, NeuroImage.

[7]  M. Vinberg,et al.  Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. , 2014, The Journal of clinical psychiatry.

[8]  J. Bukh,et al.  Recombinant Human Erythropoietin for Treating Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial , 2014, Neuropsychopharmacology.

[9]  Pradeep J Nathan,et al.  Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery. , 2014, Current opinion in pharmacology.

[10]  G. MacQueen,et al.  Neural correlates of cognitive remediation in patients with mood disorders , 2013, Psychiatry Research: Neuroimaging.

[11]  M. Vinberg,et al.  Effects of cognitive remediation on cognitive dysfunction in partially or fully remitted patients with bipolar disorder: study protocol for a randomized controlled trial , 2013, Trials.

[12]  I. Melle,et al.  Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta‐analysis , 2013, Acta psychiatrica Scandinavica.

[13]  R. Porter,et al.  Cognitive remediation as a treatment for major depression: A rationale, review of evidence and recommendations for future research , 2013, The Australian and New Zealand journal of psychiatry.

[14]  W. Marsden.  Synaptic plasticity in depression: Molecular, cellular and functional correlates , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[15]  R. Salvador,et al.  Bipolar depressed patients show both failure to activate and failure to de-activate during performance of a working memory task. , 2013, Journal of affective disorders.

[16]  E. Vieta,et al.  Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview , 2012, Acta psychiatrica Scandinavica.

[17]  E. Bora,et al.  Cognitive impairment in euthymic major depressive disorder: a meta-analysis , 2012, Psychological Medicine.

[18]  D. Rujescu,et al.  Common Variants of the Genes Encoding Erythropoietin and Its Receptor Modulate Cognitive Performance in Schizophrenia , 2012, Molecular medicine.

[19]  Philip D. Harvey,et al.  Meta‐analysis of the association between cognitive abilities and everyday functioning in bipolar disorder , 2012, Bipolar disorders.

[20]  M. Filippi,et al.  Multiple sclerosis: effects of cognitive rehabilitation on structural and functional MR imaging measures--an explorative study. , 2012, Radiology.

[21]  Zhi-jun Zhang,et al.  Erythropoietin attenuates 6-hydroxydopamine-induced apoptosis via glycogen synthase kinase 3β-mediated mitochondrial translocation of Bax in PC12 cells , 2012, Neurological Sciences.

[22]  C. Harmer,et al.  Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression , 2011, Psychopharmacology.

[23]  J. Bodurka,et al.  Physiological noise effects on the flip angle selection in BOLD fMRI , 2011, NeuroImage.

[24]  Allan L Reiss,et al.  Aberrant brain activation during a working memory task in psychotic major depression. , 2011, The American journal of psychiatry.

[25]  O. Paulson,et al.  Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder , 2010, Trials.

[26]  Catherine A. Sugar,et al.  fMRI abnormalities in dorsolateral prefrontal cortex during a working memory task in manic, euthymic and depressed bipolar subjects , 2010, Psychiatry Research: Neuroimaging.

[27]  P. Cowen,et al.  Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study , 2009, Psychopharmacology.

[28]  M. Mintun,et al.  The default mode network and self-referential processes in depression , 2009, Proceedings of the National Academy of Sciences.

[29]  Nick F. Ramsey,et al.  Within-subject variation in BOLD-fMRI signal changes across repeated measurements: Quantification and implications for sample size , 2008, NeuroImage.

[30]  W. Paulus,et al.  Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. , 2007, Brain : a journal of neurology.

[31]  C. Harmer,et al.  Erythropoietin Enhances Hippocampal Response during Memory Retrieval in Humans , 2007, The Journal of Neuroscience.

[32]  J L Lancaster,et al.  Prefrontal hyperactivation during working memory task in untreated individuals with major depressive disorder , 2007, Molecular Psychiatry.

[33]  J. Aldenhoff,et al.  Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin , 2007, Molecular Psychiatry.

[34]  M. Thase,et al.  Increased Amygdala and Decreased Dorsolateral Prefrontal BOLD Responses in Unipolar Depression: Related and Independent Features , 2007, Biological Psychiatry.

[35]  Judith Jaeger,et al.  Neurocognitive deficits and disability in major depressive disorder , 2006, Psychiatry Research.

[36]  Rong Wang,et al.  Transient blood pressure changes affect the functional magnetic resonance imaging detection of cerebral activation , 2006, NeuroImage.

[37]  Richard Levy,et al.  Cognitive control and brain resources in major depression: An fMRI study using the n-back task , 2005, NeuroImage.

[38]  Mark W. Woolrich,et al.  Multilevel linear modelling for FMRI group analysis using Bayesian inference , 2004, NeuroImage.

[39]  Paul J. Laurienti,et al.  An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets , 2003, NeuroImage.

[40]  G. Shulman,et al.  INAUGURAL ARTICLE by a Recently Elected Academy Member:A default mode of brain function , 2001 .

[41]  P Ghezzi,et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Torrens.  Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .

[43]  J. Grier,et al.  Nonparametric indexes for sensitivity and bias: computing formulas. , 1971, Psychological bulletin.

[44]  W. Drevets,et al.  Neural circuitry and neuroplasticity in mood disorders: Insights for novel therapeutic targets , 2011, NeuroRX.

[45]  E. Smith,et al.  Neuroimaging studies of working memory: A meta-analysis , 2010 .

[46]  C. Harmer,et al.  Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration , 2007, Experimental Brain Research.

[47]  P. Falkai,et al.  Erythropoietin: a candidate compound for neuroprotection in schizophrenia , 2004, Molecular Psychiatry.

[48]  R. Coppola,et al.  Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. , 1999, Cerebral cortex.

[49]  Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics Therapeutic Potential of Erythropoietin and its Structural or Functional Variants in the Nervous System , 2022 .